CERE News and Press, Ceres Inc. From 06/15/23

Mr. Burgess will be responsible for leading Cerevel’s business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling th...

2023-06-06 07:35:31 ET Summary Karuna Therapeutics' KarXT for schizophrenia is a much-hyped asset. However, there are small signs of trouble - probably nothing, but they are there. The current price seems to have priced in all these major pros and minor cons. Karuna ...

2023-06-04 06:38:16 ET Summary Cerevel has some interesting data in various CNS indications. However, the company has a very high valuation. It seems a lot of the company's potential is baked into its price. I covered Cerevel ( CERE ) two years ago. Cerevel is a ...

2023-05-10 07:03:05 ET Cerevel Therapeutics ( NASDAQ: CERE ) appointed Susan Altschuller as CFO, effective May 15. Altschuller previously served as CFO of ImmunoGen ( IMGN ) and has also worked at Alexion, now a part of AstraZeneca. Mark Bodenrader ...

Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- C...

2023-05-07 05:12:10 ET Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2023 Earnings Conference Call May 03, 2023, 8:00 AM ET Company Participants Matthew Calistri - Vice President, Corporate Strategy and Investor Relations Tony Coles - Chairperson and Chief Executive ...

2023-05-03 06:56:43 ET Pfizer ( PFE ) spinout Cerevel Therapeutics ( NASDAQ: CERE ) on Wednesday named Ron Renaud, a former Partner of Bain Capital Life Sciences its new chief executive, effective June 12, 2023. Renaud will replace Tony Coles, 62, who will step down from his...

2023-05-03 06:34:18 ET Cerevel Therapeutics press release ( NASDAQ: CERE ): Q1 GAAP EPS of -$0.67 in-line. Cash, cash equivalents, and marketable securities of $863.0 million as of March 31, 2023, expected to support seven data readouts in 2024 and fund operations into 2...

Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to Cerevel, including two prior CEO roles and strong financial and operational experience Em...

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 20...